In re Cheniere Energy Inc. Stockholders Litigation
|Court:||Court of Chancery of the State of Delaware|
|Case Number:||C.A. No. 9710-VCL|
|Judge:||Vice Chancellor Laster|
|Case Contacts:||Mark Lebovitch, David Wales, Jeroen van Kwawegen|
On December 12, 2014, the parties in consolidated class and derivative lawsuits brought on behalf of the public stockholders of Cheniere Energy, Inc. entered into a proposed settlement of the action. The lawsuits were brought against Cheniere’s CEO, certain other senior executives, and the members of its board of directors. The complaints alleged that Cheniere’s management team and board breached the terms of the company’s bylaws as well as their fiduciary duties to the Company and its shareholders, with respect to stock awards made in 2013 and in a proxy statement issued in advance of an Annual Stockholder Meeting that was, at the time of the case filing, scheduled for June 12, 2014.
The settlement includes the following terms: (1) the Company agreed to certain restrictions on the use for compensation purposes of approximately 7.845 million Available Shares absent a new stockholder vote, which must be held under a voting standard of a majority of the shares present and entitled to vote; (2) the Company agreed to certain restrictions on the amount of stock Cheniere’s CEO could receive from the Available Shares in the event of stockholder approval; (3) the Company agreed to modify the voting standard for all compensation-related votes over approximately the next seven and a half years, that is, until September 17, 2022; (4) the Company agreed to defer seeking stockholder approval for any further stock-based compensation until 2017, irrespective of the outcome of the vote on the 7.845 million Available Shares; and (5) the Company agreed that the board's compensation committee will consist entirely of independent directors. Please note that all capitalized terms are defined in Stipulation and Agreement of Compromise, Settlement and Release (the “Settlement Agreement”), which is available here.
This is only a brief summary of the terms of the Settlement. The full terms are included in the Settlement Agreement.
Other Cases of Interest
Northern District of California John Rizio-Hamilton, Mark Lebovitch, Jonathan D. Uslaner, Abe Alexander, Nicholas Gersh
Southern District of New York John C. Browne, David Wales, John Rizio-Hamilton, Jeremy P. Robinson, Laura Lefkowitz, Catherine E. van Kampen
Merck & Co., Inc. (Vioxx-Related)
District of New Jersey Salvatore J. Graziano, Katherine M. Sinderson, David Wales, Adam H. Wierzbowski, Abe Alexander, Catherine E. van Kampen
Southern District of New York Jeroen van Kwawegen, Jonathan D. Uslaner, Lauren M. Cruz, Will Horowitz
Southern District of New York Salvatore J. Graziano, Mark Lebovitch, Michael D. Blatchley, Jai K. Chandrasekhar, R. Ryan Dykhouse
Columbia Pipeline Group, Inc.
Delaware Chancery Court Mark Lebovitch, Jeroen van Kwawegen, Christopher J. Orrico, Alla Zayenchik
Biomarin Pharmaceuticals, Inc.
Northern District of California Jonathan D. Uslaner, Jeroen van Kwawegen, Avi Josefson, Thomas Sperber
Delaware Court of Chancery Mark Lebovitch, Gregory V. Varallo, Thomas James
District of Connecticut Salvatore J. Graziano, Jeroen van Kwawegen, Adam H. Wierzbowski, Scott R. Foglietta, Kate Aufses, Matthew Traylor
Northern District of California Salvatore J. Graziano, Jeroen van Kwawegen, Jeremy P. Robinson, Rebecca E. Boon, R. Ryan Dykhouse, Larry Hosmer, Steve Imundo, Andrew Boruch, Ryan Candee, Brian Chau